- Home
- SNDX vs LMB Comparison
SNDX vs LMB Comparison
Compare SNDX & LMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- LMB
- Stock Information
- Founded
- SNDX 2005
- LMB 1901
- Country
- SNDX United States
- LMB United States
- Employees
- SNDX N/A
- LMB N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- LMB Engineering & Construction
- Sector
- SNDX Health Care
- LMB Consumer Discretionary
- Exchange
- SNDX Nasdaq
- LMB Nasdaq
- Market Cap
- SNDX 1.1B
- LMB 1.6B
- IPO Year
- SNDX 2016
- LMB 2014
- Fundamental
- Price
- SNDX $9.12
- LMB $140.10
- Analyst Decision
- SNDX Strong Buy
- LMB Strong Buy
- Analyst Count
- SNDX 11
- LMB 3
- Target Price
- SNDX $35.91
- LMB $123.00
- AVG Volume (30 Days)
- SNDX 1.8M
- LMB 182.5K
- Earning Date
- SNDX 07-31-2025
- LMB 08-05-2025
- Dividend Yield
- SNDX N/A
- LMB N/A
- EPS Growth
- SNDX N/A
- LMB 31.50
- EPS
- SNDX N/A
- LMB 2.78
- Revenue
- SNDX $43,722,000.00
- LMB $532,913,000.00
- Revenue This Year
- SNDX $426.77
- LMB $20.01
- Revenue Next Year
- SNDX $98.31
- LMB $5.84
- P/E Ratio
- SNDX N/A
- LMB $50.96
- Revenue Growth
- SNDX N/A
- LMB 3.62
- 52 Week Low
- SNDX $8.58
- LMB $48.17
- 52 Week High
- SNDX $25.07
- LMB $144.00
- Technical
- Relative Strength Index (RSI)
- SNDX 38.53
- LMB 60.11
- Support Level
- SNDX $11.00
- LMB $132.65
- Resistance Level
- SNDX $11.83
- LMB $143.00
- Average True Range (ATR)
- SNDX 0.54
- LMB 5.11
- MACD
- SNDX -0.12
- LMB -1.20
- Stochastic Oscillator
- SNDX 18.12
- LMB 70.10
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About LMB Limbach Holdings Inc.
Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.